GMDI 2024 poster: APHENITY extension study dietary Phe Tolerance Assessment design using 3-day diet records: An interim report
This poster, presented at GMDI 2024, describes the APHENITY extension study phenylalanine (Phe) tolerance assessment design and reports on the compliance rate for 3-day diet diaries among participants
Learn more about sepiapterin, an investigational oral treatment for phenylketonuria (PKU)
Review the APHENITY extension study and its primary endpoints
Understand the compliance rates in using a 3-day diet diary to assess Phe tolerance changes in individuals with PKU treated with sepiapterin
Sepiapterin is an investigational product and is not currently approved in any country.
This poster was developed and funded by PTC Therapeutics for GMDI 2024.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-PKU-2400096 | April 2024
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | October 2023
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.